Medical devices, healthcare technology and the business of care
510(k) clearance · K262043

MEDRAD MRXperion MR Injection System and MR Injection System Syringe Kit; MEDRAD IS12 Module (IS12); MEDRAD Imaging Bulk Package Transfer Spike

Bayer Medical Care, Inc. · Decision date Oct 6, 2026

MEDTECHLEDGER EXPLANATIONK262043

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-10-06 for K262043, a traditional 510(k) received 06/17/2026 from Bayer Medical Care, Inc. of Indianola, Pennsylvania. The listed device name covers the MEDRAD® MRXperion MR Injection System and MR Injection System Syringe Kit, the MEDRAD® IS12 Module (IS12), and the MEDRAD® Imaging Bulk Package Transfer Spike. The classification name is Injector And Syringe, Angiographic, under regulation 870.1650, with product code DXT and subsequent product code PQH; the regulation medical specialty is Cardiovascular and the review panel General Hospital.

SESE means FDA found the submission substantially equivalent to a legally marketed predicate device; it is a 510(k) clearance, not premarket approval. The page states the submission was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan. The record does not identify the predicate device, describe the specific changes or components submitted, or include a summary statement, so the technical basis for the equivalence finding remains unknown from this source.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Oct 6, 2026
FDA decision documents: 510(k) Premarket Notification - FDA

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262043
Regulatory pathway
510(k) premarket notification
Product code
DXT
Decision code
SESE
Decision date
Oct 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Injector And Syringe, Angiographic.

Product code
DXT
FDA device class
2

FDA decision timeline

  1. K262043 received

    Application receipt date recorded by FDA.

  2. K262043 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DXT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bayer Medical Care, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Indianola, PA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records